Reports Q4 revenue $3.88B, consensus $3.93B. "It is a huge pleasure to be leading the Company through my first reporting period as CEO of Teva. The tremendous work that has been done to get the business back to a solid foundation serves as excellent grounds to transition into a new path for growth."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TEVA:
- Israel’s TEVA, PERI Tank on Q4 Earnings; IZRL in Focus
- Evoke Pharma says joint stipulation of dismissal filed in GIMOTI case
- ANDA filing for generic Firdapse not a surprise, says Piper Sandler
- CPRX Plunges as Teva Targets Its Main LEMS Treatment
- Catalyst comments on the FDA’s position on orphan drug exclusivity